The Guardant360 CDx test is a genomic testing option for solid cancers that has been approved by the FDA. It provides doctors with comprehensive results within a week of a simple blood draw, which allows for more efficient treatment decisions. Unlike traditional tissue biopsy methods, this blood test allows for a greater number of patients to benefit from targeted therapies that have been approved by the FDA. This test covers all genes recommended by the National Comprehensive Cancer Network, including the 55 most relevant to clinical care. Additionally, it has been approved as a companion diagnostic to identify patients with non-small cell lung cancer who may benefit from treatment with certain drugs such as TAGRISSO, RYBREVANT, ENHERTU and LUMAKRAS.